目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例...目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例,分为PE组、PBA组、联合组,观察3组患者治疗前后丙氨酸转氨酶(alanine aminotransferase,ALT)、总胆红素(total bilirubin,TBIL)、白蛋白(albumin,ALB)、凝血酶原时间(prothrombin time,PT)、凝血酶原时间活动度(prothrombin time activity,PTA)、肌酐(creatinine,Cr)和血氨的水平,并观察不良反应的发生率.结果:(1)联合组总有效率65.45%,高于PE组和PBA组的62.5%和59.58%,但差异无统计学意义(P>0.05);(2)PE组、PBA组、联合组患者治疗前及治疗后4hTBIL分别为:410.3mol/L±208.6mol/Lvs292.5mol/L±175.4mol/L,432.7mol/L±242.5mol/Lvs298.8mol/L±201.7mol/L,468.2mol/L±241.6mol/Lvs288.5mol/L±184.5mol/L,治疗后3组TBIL均明显下降(P<0.05),下降幅度3组间差异无意义;(3)联合组和PE组治疗后PT缩短,PTA升高(P<0.05),两组间差异无意义(P>0.05);(4)3组患者治疗后血氨均显著降低(P<0.05),但3组间无显著统计学差异(P>0.05);(5)3组患者治疗后Cr均下降(P<0.05),但3组间差异无统计学意义(P>0.05);(6)未发生严重不良反应;(7)单次血浆用量,联合组1107.1mL±212.3mL,明显少于PE组的2911.5mL±352.3mL(P<0.05).结论:PE+PBA应用血浆量少,治疗乙型肝炎肝衰竭安全、有效.展开更多
In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma(HCC). One such combined strategy is based on the combination of the percutaneous approach, ...In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma(HCC). One such combined strategy is based on the combination of the percutaneous approach, such as radiofrequency ablation(RFA), and the intra-arterial locoregional approach, such as trans-arterial chemoembolization(TACE). Several types of evidence have supported the feasibility and benefit of combined therapy, despite some studies reporting conflicting results and outcomes. The aim of this review was to explain the technical aspects of different combined treatments and to comprehensively analyze and compare the clinical efficacy and safety of this combined treatment option and monotherapy, either as TACE or RFA alone, in order to provide clinicians with an unbiased opinion and valuable information. Based on a literature review and our experience, combined treatment seems to be a safe and effective option in the treatment of patients with early/intermediate HCC when surgical resection is not feasible; furthermore, this approach provides better results than RFA and TACE alone for the treatment of large HCC, defined as those exceeding 3 cm in size. It can also expand the indication for RFA to previously contraindicated "complex cases", with increased risk of thermal ablation related complications due to tumor location, or to "complex patients" with high bleeding risk.展开更多
文摘目的:观察血浆置换(plasma exchange,PE)、血浆胆红素吸附(plasma specific bilirubin adsorption,PBA)与PE+PBA(联合组)治疗乙型肝炎肝衰竭的临床疗效,探讨乙型肝炎肝衰竭的最佳人工肝治疗方法.方法:回顾性分析乙型肝炎肝衰竭患者150例,分为PE组、PBA组、联合组,观察3组患者治疗前后丙氨酸转氨酶(alanine aminotransferase,ALT)、总胆红素(total bilirubin,TBIL)、白蛋白(albumin,ALB)、凝血酶原时间(prothrombin time,PT)、凝血酶原时间活动度(prothrombin time activity,PTA)、肌酐(creatinine,Cr)和血氨的水平,并观察不良反应的发生率.结果:(1)联合组总有效率65.45%,高于PE组和PBA组的62.5%和59.58%,但差异无统计学意义(P>0.05);(2)PE组、PBA组、联合组患者治疗前及治疗后4hTBIL分别为:410.3mol/L±208.6mol/Lvs292.5mol/L±175.4mol/L,432.7mol/L±242.5mol/Lvs298.8mol/L±201.7mol/L,468.2mol/L±241.6mol/Lvs288.5mol/L±184.5mol/L,治疗后3组TBIL均明显下降(P<0.05),下降幅度3组间差异无意义;(3)联合组和PE组治疗后PT缩短,PTA升高(P<0.05),两组间差异无意义(P>0.05);(4)3组患者治疗后血氨均显著降低(P<0.05),但3组间无显著统计学差异(P>0.05);(5)3组患者治疗后Cr均下降(P<0.05),但3组间差异无统计学意义(P>0.05);(6)未发生严重不良反应;(7)单次血浆用量,联合组1107.1mL±212.3mL,明显少于PE组的2911.5mL±352.3mL(P<0.05).结论:PE+PBA应用血浆量少,治疗乙型肝炎肝衰竭安全、有效.
文摘In recent years, a combination of intervention therapies has been widely applied in the treatment of hepatocellular carcinoma(HCC). One such combined strategy is based on the combination of the percutaneous approach, such as radiofrequency ablation(RFA), and the intra-arterial locoregional approach, such as trans-arterial chemoembolization(TACE). Several types of evidence have supported the feasibility and benefit of combined therapy, despite some studies reporting conflicting results and outcomes. The aim of this review was to explain the technical aspects of different combined treatments and to comprehensively analyze and compare the clinical efficacy and safety of this combined treatment option and monotherapy, either as TACE or RFA alone, in order to provide clinicians with an unbiased opinion and valuable information. Based on a literature review and our experience, combined treatment seems to be a safe and effective option in the treatment of patients with early/intermediate HCC when surgical resection is not feasible; furthermore, this approach provides better results than RFA and TACE alone for the treatment of large HCC, defined as those exceeding 3 cm in size. It can also expand the indication for RFA to previously contraindicated "complex cases", with increased risk of thermal ablation related complications due to tumor location, or to "complex patients" with high bleeding risk.
